Search
for
Sort by
Research 30 of 1000+
- Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
- Alopecia Areata–Specific Patient-Reported Outcome Measures
- Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA
- CO149 Does the EQ-5D Measure the Full Impact of Alopecia Areata on Patients' Health Related Quality of Life?
- BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
- Beyond Hair Regrowth: Interpreting the Psychosocial Impact of Ritlecitinib in Alopecia Areata
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial
- Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
- Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review
- Estimation of health utility values for alopecia areata
- Establishing and prioritizing research questions for the prevention, diagnosis and treatment of hair loss (excluding alopecia areata): the Hair Loss Priority Setting Partnership
- An Evaluation of Generic and Disease‐Specific Patient‐Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health‐Related Quality of Life in a European Population
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Using artificial intelligence to analyze publicly available social media posts to understand patient perspectives toward specific treatments of alopecia areata
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Alopecia: the questions we need to answer
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Alopecia Areata: Current Treatments and New Directions
- Dermatology Patient Support Groups
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata